

## GOV. MSG. NO. 581

## **EXECUTIVE CHAMBERS**

HONOLULU

LINDA LINGLE GOVERNOR

May 19, 2010

The Honorable Colleen Hanabusa, President and Members of the Senate Twenty-Fifth State Legislature State Capitol, Room 409 Honolulu, Hawaii 96813

Dear Madam President and Members of the Senate:

This is to inform you that on May 19, 2010, the following bill was signed into law:

SB2745 SD2 HD1 CD1

A BILL FOR AN ACT RELATING TO CONTROLLED SUBSTANCES. **ACT 123 (10)** 

Sincerely,

LINDA LINGLE

Approved by the Governor MAY 1 9 2010

THE SENATE TWENTY-FIFTH LEGISLATURE, 2010 STATE OF HAWAII ACT 123

S.B. NO. 5.1

C.D. 1

## A BILL FOR AN ACT

RELATING TO CONTROLLED SUBSTANCES.

## BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

- Section 329-14, Hawaii Revised Statutes, is 1 SECTION 1. 2 amended by amending subsection (d) to read as follows: Any material, compound, mixture, or preparation that 3 " (d) contains any quantity of the following hallucinogenic 4 substances, their salts, isomers, and salts of isomers, unless 5 specifically excepted, whenever the existence of these salts, 6 7 isomers, and salts of isomers is possible within the specific 8 chemical designation: 9 Alpha-ethyltryptamine (AET); (1) 2,5-dimethoxy-4-ethylamphetamine (DOET); 10 (2) 11 (3) 2,5-dimethoxyamphetamine (2,5-DMA); 12 3,4-methylenedioxy amphetamine; (4)3,4-methylenedioxymethamphetamine (MDMA); 13 (5) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-14 (6) MDA); 15 3,4-methylenedioxy-N-ethylamphetamine (MDE); 16 (7).17 (8) 5-methoxy-3,4-methylenedioxy-amphetamine; 18 4-bromo-2,5-dimethoxy-amphetamine(4-bromo-2,5-DMA); 2010-1975 SB2745 CD1 SMA.doc
  - 2010-1975 SB2745 CD1 SMA.doc

```
1
                4-Bromo-2,5-dimethoxyphenethylamine (Nexus);
         (10)
 2
                3,4,5-trimethoxy amphetamine;
         (11)
 3
         (12)
               Bufotenine;
 4
               4-methoxyamphetamine (PMA);
         (13)
               Diethyltryptamine;
 5
         (14)
               Dimethyltryptamine;
 6
         (15)
 7
         (16)
               4-methyl-2,5-dimethoxy-amphetamine;
 8
               Gamma hydroxybutyrate (GHB) (some other names include
         (17)
 9
               gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-
               hydroxybutanoic acid; sodium oxybate; sodium
10
               oxybutyrate);
11
12
         (18)
               Iboqaine;
               Lysergic acid diethylamide;
13
         (19)
14
               Marijuana;
         (20)
15
         (21)
               Parahexyl;
               Mescaline;
16
         (22)
17
         (23)
               Peyote;
               N-ethyl-3-piperidyl benzilate;
         (24)
18
19
         (25)
               N-methyl-3-piperidyl benzilate;
20
               Psilocybin;
         (26)
21
         (27)
               Psilocyn;
22
         (28)
               1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);
```

2010-1975 SB2745 CD1 SMA.doc

```
1
               Tetrahydrocannabinols;
         (29)
               Ethylamine analog of phencyclidine (PCE);
 2
         (30)
  3
               Pyrrolidine analog of phencyclidine (PCPy, PHP);
         (31)
               Thiophene analog of phencyclidine (TPCP; TCP);
         (32)
         (33)
               Gamma-butyrolactone, including butyrolactone;
  5
 6
               butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone
 7
               dihydro; dihydro-2(3H)-furanone; tetrahydro-2-
               furanone; 1,2-butanolide; 1,4-butanolide; 4-
 8
               butanolide; gamma-hydroxybutyric acid lactone; 3-
 9
               hydroxybutyric acid lactone and 4-hydroxybutanoic acid
10
               lactone with Chemical Abstract Service number 96-48-0
11
12
               when any such substance is intended for human
13
               ingestion;
14
               1,4 butanediol, including butanediol; butane-1,4-diol;
         (34)
15
               1,4- butylenes glycol; butylene glycol; 1,4-
               dihydroxybutane; 1,4- tetramethylene glycol;
16
17
               tetramethylene glycol; tetramethylene 1,4- diol with
18
               Chemical Abstract Service number 110-63-4 when any
19
               such substance is intended for human ingestion;
20
               2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7),
         (35)
               its optical isomers, salts, and salts of isomers;
21
```

```
N-benzylpiperazine (BZP; 1-benzylpiperazine) its
 1
         (36)
               optical isomers, salts, and salts of isomers;
 2
               1-(3-trifluoromethylphenyl)piperazine (TFMPP), its
 3
         (37)
 4
               optical isomers, salts, and salts of isomers;
               Alpha-methyltryptamine (AMT), its isomers, salts, and
         (3.8)
 5
               salts of isomers; [and]
 6
               5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT), its
 7
         (39)
               isomers, salts, and salts of isomers [-];
 8
               Salvia divinorum;
 9
        (40)
               Salvinorin A; and
10
        (41)
              Divinorin A."
11
        (42)
         SECTION 2. Section 329-16, Hawaii Revised Statutes, is
12
13
    amended by amending subsection (c) to read as follows:
14
               Any of the following opiates, including their
    isomers, esters, ethers, salts, and salts of isomers, whenever
15
    the existence of these isomers, esters, ethers, and salts is
16
    possible within the specific chemical designation:
17
         (1)
              Alfentanil;
18
              Alphaprodine;
19
         (2)
20
         (3)
              Anileridine;
         (4)
              Bezitramide;
21
              Bulk Dextropropoxyphene (nondosage form);
22
         (5)
```

```
1
           (6)
                Carfentanil;
 2
           (7)
                Dihydrocodeine;
 3
          (8)
               Diphenoxylate;
          (9)
                Fentanyl;
 4
 5
                Isomethadone;
         (10)
               Levo-alphacetylmethadol (LAAM);
 6
         (11)
 7
         (12)
               Levomethorphan;
 8
         (13)
               Levorphanol;
 9
         (14)
               Metazocine;
10
               Methadone;
         (15)
11
         (16)
               Methadone-Intermediate, 4-cyano-2-dimethylamino-4,
               4-dphenyl butane;
12
13
               Moramide-Intermediate, 2-methyl-3-morpholino-1,
         (17)
14
               1-diphenyl-propane-carboxylic acid;
15
         (18)
               Pethidine (Meperidine);
16
               Pethidine-Intermediate-A, 4-cyano-1-methyl-4-
         (19)
               phenylpiperidine;
17
18
         (20)
               Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-
19
               4-carboxylate;
20
               Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-
         (21)
21
               4-carboxylic acid;
22
         (22)
               Phenazocine;
```

2010-1975 SB2745 CD1 SMA.doc

```
Piminodine;
 1
         (23)
 2
         (24)
               Racemethorphan;
 3
               Racemorphan;
         (25)
               Remifentanil; [and]
         (26)
 4
               Sufentanil[-]; and
 5
         (27)
               Tapentadol."
 6
         (28)
 7
          SECTION 3. Section 329-20, Hawaii Revised Statutes, is
 8
    amended by amending subsection (b) to read as follows:
 9
                Depressants. Any material, compound, mixture, or
    preparation which contains any quantity of the following
10
11
    substances, including its salts, isomers, esters, ethers, and
    salts of isomers, whenever the existence of these isomers,
12
    esters, ethers, and salts is possible within the specific
13
    chemical designation, that has a degree of danger or probable
14
15
    danger associated with a depressant effect on the central
16
    nervous system:
17
               Alprazolam;
          (1)
18
          (2)
               Barbital;
19
          (3)
               Bromazepam;
20
          (4)
               Butorphanol;
          (5)
21
               Camazepam;
22
          (6)
               Carisoprodol;
```

2010-1975 SB2745 CD1 SMA.doc

```
1
                  Chloral betaine;
            (7)
  2
            (8)
                  Chloral hydrate;
  3
            (9)
                 Chlordiazepoxide;
  4
           (10)
                  Clobazam;
  5
           (11)
                 Clonazepam;
  6
                 Clorazepate;
          (12)
  7
          (13)
                 Clotiazepam;
  8
          (14)
                 Cloxazolam;
 9
          (15)
                 Delorazepam;
10
                 Dichloralphenazone (Midrin);
          (16)
11
          (17)
                 Diazepam;
12
                 Estazolam;
          (18)
13
                 Ethchlorvynol;
          (19)
14
                 Ethinamate;
          (20)
15
          (21)
                 Ethyl loflazepate;
16
          (22)
                 Fludiazepam;
17
          (23)
                 Flunitrazepam;
18
          (24)
                 Flurazepam;
19
         (25)
                 Fospropofol (Lusedra);
20
         [\frac{(25)}{}]
                (26)
                       Halazepam;
21
                       Haloxazolam;
        [\frac{(26)}{}]
                (27)
22
        [\frac{(27)}{}]
                (28)
                       Ketazolam;
     2010-1975 SB2745 CD1 SMA.doc
```

```
1
          [\frac{(28)}{}]
                          Loprazolam;
                  (29)
 2
          [\frac{(29)}{(30)}]
                          Lorazepam;
 3
          [\frac{(30)}{(31)}]
                          Lormetazepam;
 4
          [-(31)] (32)
                          Mebutamate;
 5
         [\frac{(32)}{(33)}]
                         Medazepam;
 6
         [\frac{(33)}{(34)}]
                         Meprobamate;
 7
          [\frac{(34)}{(35)}]
                         Methohexital;
 8
         [\frac{(35)}{(36)}]
                         Methylphenobarbital (mephorbarbital);
 9
                         Midazolam;
         [\frac{(36)}{(37)}]
10
         [+37)
                 (38)
                         Nimetazepam;
11
         [\frac{(38)}{(39)}]
                         Nitrazepam;
12
         [\frac{(39)}{(40)}]
                         Nordiazepam;
13
         [(40)] (41)
                         Oxazepam;
14
                         Oxazolam;
         [(41)] (42)
15
         [(42)] (43)
                         Paraldehyde;
16
         [\frac{(43)}{(44)}]
                         Petrichloral;
17
         [(44)] (45)
                         Phenobarbital;
18
         [-(45)] (46)
                         Pinazepam;
19
         [-(46)] (47)
                         Prazepam;
20
         [\frac{47}{47}] (48)
                         Quazepam;
21
         [-(48)] (49)
                         Temazepam;
22
         [-(49)]
                 (50)
                         Tetrazepam;
     2010-1975 SB2745 CD1 SMA.doc
```

```
Triazolam:
  1
         [\frac{(50)}{}] (51)
  2
         [\frac{(51)}{}] (52)
                        Zaleplon;
                       Zolpidem; and
  3
         [<del>(52)</del>] (53)
         [<del>(53)</del>] (54) Zopiclone (Lunesta)."
  4
 5
           SECTION 4. Section 329-22, Hawaii Revised Statutes, is
 6
     amended by amending subsection (d) to read as follows:
 7
           "(d) Depressants. Unless specifically exempted or
     excluded or unless listed in another schedule, any material,
 8
 9
     compound, mixture, or preparation that contains any quantity of
10
     the following substances having a depressant effect on the
     central nervous system, including its salts, isomers, and salts
11
12
     of isomers:
                Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-
13
          (1)
                propionamide], (Vimpat); and
14
15
          \left[\frac{1}{1}\right] (2) Pregabalin \left[\frac{1}{1}\right] (2) Pregabalin \left[\frac{1}{1}\right] (3) -3- (aminomethyl) -5-methylhexanoic
                acid]."
16
17
          SECTION 5. Section 329-35, Hawaii Revised Statutes, is
     amended to read as follows:
18
19
          "§329-35 Order to show cause.
                                              (a) [Before denying,
20
    suspending, or revoking a registration, or refusing a renewal of
21
    registration, the department of public safety shall serve upon
22
    the applicant or registrant an order to show cause why
    2010-1975 SB2745 CD1 SMA.doc
```

registration should not be denied, revoked, or suspended, or why 1 the renewal should not be refused. The order to show cause 2 shall contain a statement of the basis therefor and shall call 3 upon the applicant or registrant to appear before the department 4 of public safety at a time and place not less than thirty days 5 after the date of service of the order, but in the case of a 6 denial or renewal of registration the show cause order shall be 7 served not later than thirty days before the expiration of the 8 registration. These proceedings shall be conducted in 9 accordance with chapter 91 without regard to any criminal 10 prosecution or other proceeding. Proceedings to refuse renewal 11 of registration shall not abate the existing registration which 12 shall remain in effect pending the outcome of the administrative 13 hearing.] If, upon examination of the application for 14 registration from any applicant and other information gathered 15 by the department regarding the applicant, the administrator is 16 unable to make the determinations required by the applicable **17** provisions of sections 329-32 and 329-33 and applicable rules to 18 register the applicant, the administrator shall serve upon the 19 applicant an order to show cause why the registration should not 20 21 be denied.

1	(b) If, upon information gathered by the department
2	regarding any registrant, the administrator determines that the
3	registration of a registrant warrants suspension or revocation
4	pursuant to section 329-34 or applicable rules, the department
5	shall serve upon the registrant an order to show cause why the
6	registration should not be revoked or suspended.
7	(c) The order to show cause shall call upon the applicant
8	or registrant to:
9	(1) Appear before the department at a time and place
10	stated in the order, which shall not be less than
11	thirty days after the date of receipt of the order, to
12	admit to the allegations in the order to show cause;
13	nder en film en
14	(2) Request a hearing as provided in subsection (d).
15	The order to show cause shall also contain a statement of the
16	legal basis for such hearing and the reasons that support the
17	administrator's intent to deny the application, or the
18	revocation or suspension of registration, and a summary of the
19	matters of fact and law asserted.
20	(d) Upon receipt of an order to show cause, the applicant
21	or registrant, if the registrant or applicant desires a hearing,
22	shall file a request for a hearing with the department within
	2010-1975 SB2745 CD1 SMA doc

- 1 thirty days after service of the order to show cause. Failure
- 2 to request a hearing shall result in the automatic termination
- 3 of the registrant's registration and in the case of a new
- 4 application or renewal the unprocessed application shall be
- 5 returned to the applicant.
- 6 [(b) The] (e) Notwithstanding subsections (a) to (d),
- 7 department of public safety may suspend any registration
- 8 simultaneously with the institution of proceedings under section
- 9 329-34, or where renewal of registration is refused, if it finds
- 10 that there is an imminent danger to the public health or safety
- 11 which warrants this action. The suspension shall continue in
- 12 effect until the conclusion of the proceedings, including
- 13 judicial review thereof, unless sooner withdrawn by the
- 14 department of public safety or dissolved by a court of competent
- 15 jurisdiction.
- 16 [(c)] (f) The department of public safety may subpoena and
- 17 examine witnesses under oath upon all such charges as may be
- 18 [preferred] referred before it[, and the circuit court of the
- 19 circuit in which the hearing is held shall enforce by
- 20 appropriate order the attendance and testimony of witnesses so
- 21 subpoenaed]."

+	DECI	10N 0. Beetion 323 of hawari hevibea seacases, is
2	amended b	y amending subsection (a) to read as follows:
3	" (a)	The requirements imposed by sections $329-62[_{7}]$ and
4	329-63 (a)	[, and 329-67] of this part shall not apply to any of
5	the follo	wing:
6	(1)	Any pharmacist or other authorized person who sells or
7		furnishes a substance upon the prescription of a
8		physician, dentist, podiatrist, or veterinarian;
9	(2)	Any physician, dentist, podiatrist, or veterinarian
10		who administers or furnishes a substance to patients;
11	(3)	Any manufacturer or wholesaler licensed by the State
12		who sells, transfers, or otherwise furnishes a
13		substance to a licensed pharmacy, physician, dentist,
14		podiatrist, or veterinarian; and
15	(4)	Any sale, transfer, furnishing, or receipt of any drug
16		that contains pseudoephedrine or norpseudoephedrine
<b>17</b>		that is lawfully sold, transferred, or furnished over
18		the counter without a prescription pursuant to the
19		federal Food, Drug, and Cosmetic Act (21 United States
20		Code Sec. 301 et seq.) or regulations adopted
21		thereunder as long as it complies with the

1	requirements of sections 329-73, 329-74, and 329-75[ $\pm$
2	and
3	(5) Any "dietary supplement" as defined by the federal
4.	Food, Drug, and Cosmetic Act (21 United States Code
5	Sec. 301) containing ephedrine alkaloids extracted
6	from any species of Ephedra that meets all of the
7	following criteria:
8	(A) It contains, per dosage unit or serving, not more
9	than twenty-five milligrams of ephedrine
10	alkaloids and its labeling does not suggest or
11	recommend a total daily intake of more than one
12	hundred milligrams of ephedrine alkaloids;
13	(B) It contains no hydrochloride or sulfate salts of
14	ephedrine alkaloids; and
15	(C) It is packaged with a prominent label securely
16	affixed to each package that states all of the
17	<del>following:</del>
18	(i) The amount in milligrams of ephedrine
19	alkaloids in a dosage unit or serving;
20	(ii) The amount of the dietary supplement that
21	constitutes a dosage unit or serving; and

. 1	: (111) The maximum recommended dosage of ephedrine
2	alkaloids for a healthy adult human is not
3	more than one hundred milligrams in a
4	twenty-four-hour-period]."
5	SECTION 7. Section 329-101, Hawaii Revised Statutes, is
6	amended by amending subsection (f) to read as follows:
7	"(f) Intentional or knowing failure to transmit any
8	information as required by this section, including a request by
9	the designated state agency for data corrections, shall be a
10	misdemeanor, may incur administrative fines, and shall result in
11	the immediate suspension of that pharmacy or practitioner's
12	ability to dispense controlled [-] substances[-] in the [State]
13	state until authorized by the administrator."
14	SECTION 8. Section 329-104, Hawaii Revised Statutes, is
15	amended as follows:
16	1. By amending subsections (b) and (c) to read:
17	"(b) Responsibility for limiting access to information in
18	the system is vested in the administrator. Access to the
19	information collected at the central repository pursuant to this
20	part shall be confidential, and access to the information shall
21	be limited to[+

1	<del>(1)</del>	Personnel personnel of the designated state agency[+
2		and
3	<del>(2)</del>	The Drug Enforcement Administration diversion group
4		supervisor].
5	(c)	This section shall not prevent the disclosure, at the
6	discretio	n of the administrator, of investigative information
7	to:	
8	(1)	Law enforcement officers, investigative agents of
9		federal, state, or county law enforcement agencies,
10		United States attorneys, county prosecuting attorneys
11		or the attorney general; provided that the
12		administrator has reasonable grounds to believe that
13		the disclosure of any information collected under this
14		part is in furtherance of an ongoing criminal or
15		regulatory investigation or prosecution;
16	(2)	Registrants authorized under chapters 448, 453, and
17		463E who are registered to administer, prescribe, or
18		dispense controlled substances; provided that the
19		information disclosed relates only to the registrant's
20		own patient;
21	(3)	Pharmacists, employed by a pharmacy registered under
22		section 329-32, who request prescription information

6 government agency under this section shall be transmitted by a 7 secure means determined by the designated agency." 8 2. By amending subsection (e) to read: 9 "(e) The designated state agency shall purge or cause to 10 be purged from the central repository system, no later than 11 [three] five years after the date a patient's prescription data 12 are made available to the designated state agency, the 13 identification number of the patient, unless the information is 14 part of an active investigation."	1	about a customer relating to a violation or possible
monitoring programs.  Information disclosed to a registrant, pharmacist, or authorize government agency under this section shall be transmitted by a secure means determined by the designated agency."  By amending subsection (e) to read:  "(e) The designated state agency shall purge or cause to be purged from the central repository system, no later than  [three] five years after the date a patient's prescription data are made available to the designated state agency, the identification number of the patient, unless the information is part of an active investigation."  SECTION 9. Statutory material to be repealed is bracketed and stricken. New statutory material is underscored.  SECTION 10. This Act shall take effect upon its approval.	2	violation of this chapter; or
Information disclosed to a registrant, pharmacist, or authorize government agency under this section shall be transmitted by a secure means determined by the designated agency."  2. By amending subsection (e) to read:  "(e) The designated state agency shall purge or cause to be purged from the central repository system, no later than  [three] <u>five</u> years after the date a patient's prescription data are made available to the designated state agency, the identification number of the patient, unless the information is part of an active investigation."  SECTION 9. Statutory material to be repealed is bracketed and stricken. New statutory material is underscored.  SECTION 10. This Act shall take effect upon its approval.	3	(4) Other state-authorized governmental prescription-
government agency under this section shall be transmitted by a  secure means determined by the designated agency."  By amending subsection (e) to read:  "(e) The designated state agency shall purge or cause to  be purged from the central repository system, no later than  [three] five years after the date a patient's prescription data  are made available to the designated state agency, the  identification number of the patient, unless the information is  part of an active investigation."  SECTION 9. Statutory material to be repealed is bracketed  and stricken. New statutory material is underscored.  SECTION 10. This Act shall take effect upon its approval.	4	monitoring programs.
secure means determined by the designated agency."  2. By amending subsection (e) to read:  "(e) The designated state agency shall purge or cause to  be purged from the central repository system, no later than  [three] five years after the date a patient's prescription data  are made available to the designated state agency, the  identification number of the patient, unless the information is  part of an active investigation."  SECTION 9. Statutory material to be repealed is bracketed  and stricken. New statutory material is underscored.  SECTION 10. This Act shall take effect upon its approval.	5	Information disclosed to a registrant, pharmacist, or authorized
8 2. By amending subsection (e) to read: 9 "(e) The designated state agency shall purge or cause to 10 be purged from the central repository system, no later than 11 [three] five years after the date a patient's prescription data 12 are made available to the designated state agency, the 13 identification number of the patient, unless the information is 14 part of an active investigation." 15 SECTION 9. Statutory material to be repealed is bracketed 16 and stricken. New statutory material is underscored. 17 SECTION 10. This Act shall take effect upon its approval.	6	government agency under this section shall be transmitted by a
"(e) The designated state agency shall purge or cause to be purged from the central repository system, no later than [three] five years after the date a patient's prescription data are made available to the designated state agency, the identification number of the patient, unless the information is part of an active investigation."  SECTION 9. Statutory material to be repealed is bracketed and stricken. New statutory material is underscored.  SECTION 10. This Act shall take effect upon its approval.	7	secure means determined by the designated agency."
10 be purged from the central repository system, no later than  11 [three] five years after the date a patient's prescription data  12 are made available to the designated state agency, the  13 identification number of the patient, unless the information is  14 part of an active investigation."  15 SECTION 9. Statutory material to be repealed is bracketed  16 and stricken. New statutory material is underscored.  17 SECTION 10. This Act shall take effect upon its approval.	8	2. By amending subsection (e) to read:
11 [three] five years after the date a patient's prescription data 12 are made available to the designated state agency, the 13 identification number of the patient, unless the information is 14 part of an active investigation." 15 SECTION 9. Statutory material to be repealed is bracketed 16 and stricken. New statutory material is underscored. 17 SECTION 10. This Act shall take effect upon its approval.	9	"(e) The designated state agency shall purge or cause to
are made available to the designated state agency, the  identification number of the patient, unless the information is  part of an active investigation."  SECTION 9. Statutory material to be repealed is bracketed  and stricken. New statutory material is underscored.  SECTION 10. This Act shall take effect upon its approval.	10	be purged from the central repository system, no later than
<pre>13 identification number of the patient, unless the information is 14 part of an active investigation." 15 SECTION 9. Statutory material to be repealed is bracketed 16 and stricken. New statutory material is underscored. 17 SECTION 10. This Act shall take effect upon its approval.</pre>	11	[three] five years after the date a patient's prescription data
part of an active investigation."  SECTION 9. Statutory material to be repealed is bracketed  and stricken. New statutory material is underscored.  SECTION 10. This Act shall take effect upon its approval.	12	are made available to the designated state agency, the
15 SECTION 9. Statutory material to be repealed is bracketed 16 and stricken. New statutory material is underscored. 17 SECTION 10. This Act shall take effect upon its approval.	13	identification number of the patient, unless the information is
16 and stricken. New statutory material is underscored. 17 SECTION 10. This Act shall take effect upon its approval.	14	part of an active investigation."
17 SECTION 10. This Act shall take effect upon its approval.	15	SECTION 9. Statutory material to be repealed is bracketed
	16	and stricken. New statutory material is underscored.
18	17	SECTION 10. This Act shall take effect upon its approval.
	18	

APPROVED this 19 day of MAY , 2010

GOVERNOR OF THE STATE OF HAWAII